[1] 鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021,37(6):1268-1274.
[2] 尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023,36(1):1-17.
[3] Terrault N A, Lok A, McMahon B J, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Clin Liver Dis (Hoboken), 2018,12(1):33-34.
[4] Wang L J, Gu Z Q, Xu Z M, et al. A possible mechanism for low-level viremia occurrence in nucleos(t)ide analog-treated chronic hepatitis B patients[J]. Zhonghua Gan Zang Bing Za Zhi, 2021,29(12):1151-1155.
[5] Zhang Q, Cai D C, Hu P, et al. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients[J]. Chin Med J (Engl), 2021,134(23):2810-2817.
[6] Ogawa E, Nomura H, Nakamuta M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B[J]. Liver Int, 2020,40(7):1578-1589.
[7] Lee S B, Jeong J, Park J H, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir[J]. Clin Mol Hepatol, 2020,26(3):364-375.
[8] Sun Y, Wu X, Zhou J, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy[J]. Clin Gastroenterol Hepatol, 2020,18(11):2582-2591.
[9] 陈贺, 傅涓涓, 李丽, 等. 长期恩替卡韦经治慢性乙型肝炎患者低病毒血症的相关影响因素[J]. 临床肝胆病杂志, 2021,37(3):556-559.
[10] 毛少霞. 全国乙肝流行特征分析及发病预测研究[D]. 兰州财经大学, 2021.
[11] Shin S K, Yim H J, Kim J H, et al. Partial virological response after 2 years of entecavir therapy increases the risk of hepatocellular carcinoma in patients with hepatitis B virus-associated cirrhosis[J]. Gut Liver, 2021,15(3):430-439.
[12] Mak L Y, Huang Q, Wong D K, et al. Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy[J]. J Gastroenterol, 2021,56(5):479-488.
[13] Park J H, Ahn S J, Cho H J, et al. Clinical course of partial virological responders under prolonged entecavir monotherapy in patients with chronic hepatitis B[J]. J Med Virol, 2016,88(2):252-259.
[14] Kim H J, Cho Y K, Jeon W K, et al. Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: real-life experience[J]. Clin Mol Hepatol, 2017,23(4):323-330.
[15] Wong G L, Wong V W, Chan H Y, et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years[J]. Aliment Pharmacol Ther, 2012,35(11):1326-1335.
[16] Huang Y J, Yang S S, Yeh H Z, et al. Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B[J]. PLoS One, 2019,14(8):e221958.
[17] Kim J H, Sinn D H, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017,66(2):335-343.
[18] Zhang Q, Peng H, Liu X, et al. Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease[J]. J Clin Transl Hepatol, 2021,9(6):850-859.
[19] Lee H W, Park S Y, Lee Y R, et al. Episodic detectable viremia does not affect prognosis in untreated compensated cirrhosis with serum hepatitis B virus DNA <2,000 IU/mL[J]. Am J Gastroenterol, 2022,117(2):288-294.
[20] 宣碧碧, 徐永红, 杜忠彩, 等. 慢性乙型肝炎和乙型肝炎肝硬化患者发生低病毒血症的影响因素及其与肝脏炎症、肝纤维化进展的关系[J]. 临床肝胆病杂志, 2022,38(10):2252-2259.
[21] 程齐齐, 杨丽霞, 蔡天盼, 等. 核苷(酸)类似物初治的慢性乙型肝炎患者发生低病毒血症的影响因素及其动态变化分析[J]. 临床肝胆病杂志, 2022,38(12):2716-2722.
[22] Revill P A, Chisari F V, Block J M, et al. A global scientific strategy to cure hepatitis B[J]. Lancet Gastroenterol Hepatol, 2019,4(7):545-558.
[23] Deng D L, Jiang J N, Su M H, et al. Liver histological status and clinic outcome in HBeAg-negative chronic hepatitis B with low viral load[J]. Zhonghua Gan Zang Bing Za Zhi, 2020,28(12):1013-1017.
[24] 李彤. 经治慢性乙型肝炎低病毒血症患者人群特征及相关影响因素分析[D]. 兰州大学, 2022.
[25] 杨雪芳. 经治慢性乙型肝炎患者低病毒血症的临床特征及危险因素分析[D]. 昆明医科大学, 2022.
[26] Han J, Guo Y, Zhang X, et al. Prevalence and associated factors of low-level viremia in chronic hepatitis B patients after long-term therapy with nucleos(t)ide analogs[J]. Turk J Gastroenterol, 2023,34(1):53-61.
[27] Shin J W, Jung S W, Lee S B, et al. Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir[J]. Am J Gastroenterol, 2018,113(7):998-1008.
[28] Tao Y C, Wang M L, Zhang D M, et al. Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment[J]. J Viral Hepat, 2020,27(7):731-738.
[29] Tamaki N, Kurosaki M, Nakanishi H, et al. Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B[J]. J Med Virol, 2020,92(8):1355-1358.
[30] Yin G Q, Li J, Zhong B, et al. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: increase of entecavir dosage[J]. World J Gastroenterol, 2021,27(8):666-676.
[31] 陈丽文, 祝达, 谢竟全, 等. 三种抗病毒治疗方案对ETV经治低病毒血症CHB患者HBV DNA转阴时间差异分析[J]. 海南医学, 2021,32(6):689-691.
[32] Li Z B, Li L, Niu X X, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia[J]. Liver Int, 2021,41(6):1254-1264.
[33] 陈文辉, 汤智勤, 高海兵. 富马酸替诺福韦单药或联合恩替卡韦治疗恩替卡韦治疗后的低病毒血症的慢乙肝的48周疗效观察[J]. 海峡药学, 2021,33(5):177-179.
[34] 孙亚朦, 贾继东, 尤红. 2022年《扩大慢性乙型肝炎抗病毒治疗的专家意见》解读[J]. 中国临床医生杂志, 2022,50(10):1144-1146.
[35] Sulkowski M S, Agarwal K, Ma X, et al. Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection[J]. J Hepatol, 2022,77(5):1265-1275. |
